Download PDF
Fortschr Neurol Psychiatr 2009; 77(2): 72-82
DOI: 10.1055/s-0028-1109116
Originalarbeit

© Georg Thieme Verlag KG Stuttgart · New York

Somatische Faktoren bei leichten kognitiven Störungen

Somatic Factors in Cognitive ImpairmentT. Etgen1, 2 , M. Brönner2 , D. Sander3, 4 , H. Bickel2 , K. Sander3, 4 , H. Förstl2
  • 1Neurologische Klinik, Klinikum Traunstein (Chefarzt: Dr. T. Freudenberger)
  • 2Klinik für Psychiatrie und Psychotherapie, Technische Universität München (Direktor: Prof. Dr. H. Förstl)
  • 3Neurologische Klinik, Medical Park Loipl, Bischofswiesen (Chefarzt: Prof. Dr. D. Sander)
  • 4Neurologische Klinik, Technische Universität München (Direktor: Prof. Dr. B. Hemmer)
Further Information

Publication History

Publication Date:
16 February 2009 (online)

    Permissions and Reprints

Zusammenfassung

Leichte kognitive Störungen beschreiben eine häufige, über dem Durchschnitt der entsprechenden Alters- und Ausbildungsstufe liegende Einschränkung von Merkfähigkeit, Aufmerksamkeit oder Denkvermögen ohne wesentliche Störung im Alltagsleben. Der Begriff „mild cognitive impairment (MCI)“ wurde in den letzten Jahren unterschiedlich definiert und als fragliches Vorstadium demenzieller Erkrankungen diskutiert. Die Ätiologie leichter kognitiver Störungen ist heterogen und kann durch unterschiedliche somatische Erkrankungen begünstigt oder hervorgerufen werden. Zu den relevanten somatischen Faktoren gehören Bluthochdruck, Diabetes mellitus, Herzinsuffizienz, chronisch-obstruktive Lungenerkrankung und Asthma bronchiale. Eine mögliche Rolle bei der Entstehung von leichten kognitiven Störungen besitzen ferner Hypercholesterinämie, chronische Niereninsuffizienz, subklinische Hypothyreose, Testosteronmangel, minimale hepatische Enzephalopathie, HIV- und Hepatitis-C-Infektion. Daher muss bei leichten kognitiven Störungen nach somatischen Risikofaktoren gesucht werden, um diese optimal zu behandeln, da dies zu einer Leistungsverbesserung führen oder eine Progredienz verhindern kann.

Abstract

Mild cognitive impairment describes a cognitive decline greater than expected for an individual’s age and education level that does not interfere significantly with activities of daily life. In the recent years concepts of “mild cognitive impairment” with divergent definitions have been discussed as potential preclinical forms of dementia. The etiology of cognitive impairment is heterogeneous and it can be promoted or caused by numerous somatic factors. Relevant somatic factors include hypertension, diabetes mellitus, heart failure, chronic obstructive airways disease and bronchial asthma. Cognitive impairment may be facilitated by hypercholesterolemia, chronic renal failure, hypothyroidism, testosterone deficiency, minimal hepatic encephalopathy, HIV- and hepatitis C-infection. Knowledge and diagnosis of these somatic factors is essential in cognitive impairment, as diligent treatment may lead to improve cognitive performance and postpone the manifestation of dementia.

Schlüsselwörter

leichte kognitive Störungen - Demenz - somatische Risikofaktoren - Ätiologie - Prävention

Key words

mild cognitive impairment - dementia - somatic risk factors - etiology - prevention

Literatur

  • 1 Gauthier S, Reisberg B, Zaudig M. et al . Mild cognitive impairment.  Lancet. 2006;  367 1262-1270
    Google Scholar
  • 2 Kurz A, Diehl J, Riemenschneider M. et al . Leichte kognitive Störung. Fragen zu Definition, Diagnose, Prognose und Therapie.  Nervenarzt. 2004;  75 6-15
    Google Scholar
  • 3 DeCarli C. Mild cognitive impairment: prevalence, prognosis, aetiology, and treatment.  Lancet Neurol. 2003;  2 15-21
    Google Scholar
  • 4 Winblad B, Palmer K, Kivipelto M. et al . Mild cognitive impairment – beyond controversies, towards a consensus: report of the International Working Group on Mild Cognitive Impairment.  J Intern Med. 2004;  256 240-246
    Google Scholar
  • 5 Luck T, Riedel-Heller S G, Kaduszkiewicz H. et al . Mild cognitive impairment in general practice: age-specific prevalence and correlate results from the German study on ageing, cognition and dementia in primary care patients (AgeCoDe).  Dement Geriatr Cogn Disord. 2007;  24 307-316
    Google Scholar
  • 6 Graham J E, Rockwood K, Beattie B L. et al . Prevalence and severity of cognitive impairment with and without dementia in an elderly population.  Lancet. 1997;  349 1793-1796
    Google Scholar
  • 7 Förstl H, Bickel H, Frölich L. et al . Leichte kognitive Beeinträchtigung mit Vorzeichen rascher Verschlechterung.  Dtsch Med Wochenschr. 2008;  133 431-436
    Google Scholar
  • 8 Price J L, Morris J C. Tangles and plaques in nondemented aging and “preclinical” Alzheimer’s disease.  Ann Neurol. 1999;  45 358-368
    Google Scholar
  • 9 Riemenschneider M, Lautenschlager N, Wagenpfeil S. et al . Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.  Arch Neurol. 2002;  59 1729-1734
    Google Scholar
  • 10 Morris J C, Storandt M, Miller J P. et al . Mild cognitive impairment represents early-stage Alzheimer disease.  Arch Neurol. 2001;  58 397-405
    Google Scholar
  • 11 Linn R T, Wolf P A, Bachman D L. et al . The ‘preclinical phase’ of probable Alzheimer’s disease. A 13-year prospective study of the Framingham cohort.  Arch Neurol. 1995;  52 485-490
    Google Scholar
  • 12 DeCarli C, Miller B L, Swan G E. et al . Cerebrovascular and brain morphologic correlates of mild cognitive impairment in the National Heart, Lung, and Blood Institute Twin Study.  Arch Neurol. 2001;  58 643-647
    Google Scholar
  • 13 Seux M L, Forette F. Effects of hypertension and its treatment on mental function.  Curr Hypertens Rep. 1999;  1 232-237
    Google Scholar
  • 14 Birkenhager W H, Forette F, Seux M L. et al . Blood pressure, cognitive functions, and prevention of dementias in older patients with hypertension.  Arch Intern Med. 2001;  161 152-156
    Google Scholar
  • 15 Elias M F, Wolf P A, D’Agostino R B. et al . Untreated blood pressure level is inversely related to cognitive functioning: the Framingham Study.  Am J Epidemiol. 1993;  138 353-364
    Google Scholar
  • 16 Launer L J, Masaki K, Petrovitch H. et al . The association between midlife blood pressure levels and late-life cognitive function. The Honolulu-Asia Aging Study.  J Am Med Assoc. 1995;  274 1846-1851
    Google Scholar
  • 17 Tzourio C, Dufouil C, Ducimetiere P. et al . Cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly. EVA Study Group. Epidemiology of Vascular Aging.  Neurology. 1999;  53 1948-1952
    Google Scholar
  • 18 Prince M J, Bird A S, Blizard R A. et al . Is the cognitive function of older patients affected by antihypertensive treatment? Results from 54 months of the Medical Research Council’s trial of hypertension in older adults.  Brit Med J. 1996;  312 801-805
    Google Scholar
  • 19 Applegate W B, Pressel S, Wittes J. et al . Impact of the treatment of isolated systolic hypertension on behavioral variables. Results from the systolic hypertension in the elderly program.  Arch Intern Med. 1994;  154 2154-2160
    Google Scholar
  • 20 Lithell H, Hansson L, Skoog I. et al . The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial.  J Hypertens. 2003;  21 875-886
    Google Scholar
  • 21 Forette F, Seux M L, Staessen J A. et al . Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial.  Lancet. 1998;  352 1347-1351
    Google Scholar
  • 22 Tzourio C, Anderson C, Chapman N. et al . Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease.  Arch Intern Med. 2003;  163 1069-1075
    Google Scholar
  • 23 McGuinness B, Todd S, Passmore P. et al . The effects of blood pressure lowering on development of cognitive impairment and dementia in patients without apparent prior cerebrovascular disease.  Cochrane Database Syst Rev. 2006 Apr 19;  (2) CD004034
    Google Scholar
  • 24 Poon I O. Effects of antihypertensive drug treatment on the risk of dementia and cognitive impairment.  Pharmacotherapy. 2008;  28 366-375
    Google Scholar
  • 25 Skoog I, Lernfelt B, Landahl S. et al . 15-year longitudinal study of blood pressure and dementia.  Lancet. 1996;  347 1141-1145
    Google Scholar
  • 26 Cardiogenic Dementia.  Lancet. 1977;  1 27-28
    Google Scholar
  • 27 Vogels R L, Scheltens P, Schroeder-Tanka J M. et al . Cognitive impairment in heart failure: a systematic review of the literature.  Eur J Heart Fail. 2007;  9 440-449
    Google Scholar
  • 28 Deshields T L, McDonough E M, Mannen R K. et al . Psychological and cognitive status before and after heart transplantation.  Gen Hosp Psychiatry. 1996;  18 62S-69S
    Google Scholar
  • 29 Koide H, Kobayashi S, Kitani M. et al . Improvement of cerebral blood flow and cognitive function following pacemaker implantation in patients with bradycardia.  Gerontology. 1994;  40 279-285
    Google Scholar
  • 30 Grant I, Heaton R K, McSweeny A J. et al . Neuropsychologic findings in hypoxemic chronic obstructive pulmonary disease.  Arch Intern Med. 1982;  142 1470-1476
    Google Scholar
  • 31 Prigatano G P, Parsons O, Wright E. et al . Neuropsychological test performance in mildly hypoxemic patients with chronic obstructive pulmonary disease.  J Consult Clin Psychol. 1983;  51 108-116
    Google Scholar
  • 32 Grant I, Prigatano G P, Heaton R K. et al . Progressive neuropsychologic impairment and hypoxemia. Relationship in chronic obstructive pulmonary disease.  Arch Gen Psychiatry. 1987;  44 999-1006
    Google Scholar
  • 33 Hjalmarsen A, Waterloo K, Dahl A. et al . Effect of long-term oxygen therapy on cognitive and neurological dysfunction in chronic obstructive pulmonary disease.  Eur Neurol. 1999;  42 27-35
    Google Scholar
  • 34 Incalzi R A, Gemma A, Marra C. et al . Chronic obstructive pulmonary disease. An original model of cognitive decline.  Am Rev Respir Dis. 1993;  148 418-424
    Google Scholar
  • 35 Heaton R K, Grant I, McSweeny A J. et al . Psychologic effects of continuous and nocturnal oxygen therapy in hypoxemic chronic obstructive pulmonary disease.  Arch Intern Med. 1983;  143 1941-1947
    Google Scholar
  • 36 Krop H D, Block A J, Cohen E. Neuropsychologic effects of continuous oxygen therapy in chronic obstructive pulmonary disease.  Chest. 1973;  64 317-322
    Google Scholar
  • 37 Liesker J J, Postma D S, Beukema R J. et al . Cognitive performance in patients with COPD.  Respir Med. 2004;  98 351-356
    Google Scholar
  • 38 Fitzpatrick M F, Engleman H, Whyte K F. et al . Morbidity in nocturnal asthma: sleep quality and daytime cognitive performance.  Thorax. 1991;  46 569-573
    Google Scholar
  • 39 Weersink E J, Zomeren E H, Koeter G H. et al . Treatment of nocturnal airway obstruction improves daytime cognitive performance in asthmatics.  Am J Respir Crit Care Med. 1997;  156 1144-1150
    Google Scholar
  • 40 Gregg E W, Yaffe van K, Cauley J A. et al . Is diabetes associated with cognitive impairment and cognitive decline among older women? Study of Osteoporotic Fractures Research Group.  Arch Intern Med. 2000;  160 174-180
    Google Scholar
  • 41 Logroscino G, Kang J H, Grodstein F. Prospective study of type 2 diabetes and cognitive decline in women aged 70 – 81 years.  Brit Med J. 2004;  328 548
    Google Scholar
  • 42 Yaffe K, Blackwell T, Kanaya A M. et al . Diabetes, impaired fasting glucose, and development of cognitive impairment in older women.  Neurology. 2004;  63 658-663
    Google Scholar
  • 43 Okereke O I, Kang J H, Cook N R. et al . Type 2 Diabetes Mellitus and Cognitive Decline in Two Large Cohorts of Community-Dwelling Older Adults.  J Am Geriatr Soc. 2008;  56 1028-1036
    Google Scholar
  • 44 Brands A M, Biessels G J, Haan E H. et al . The effects of type 1 diabetes on cognitive performance: a meta-analysis.  Diabetes Care. 2005;  28 726-735
    Google Scholar
  • 45 Ryan C M. Diabetes, aging, and cognitive decline.  Neurobiol Aging. 2005;  26 (Suppl 1) 21-25
    Google Scholar
  • 46 Brownlee de M. Biochemistry and molecular cell biology of diabetic complications.  Nature. 2001;  414 813-820
    Google Scholar
  • 47 Pappolla M A, Bryant-Thomas T K, Herbert D. et al . Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology.  Neurology. 2003;  61 199-205
    Google Scholar
  • 48 Roher A E, Esh C, Kokjohn T A. et al . Circle of willis atherosclerosis is a risk factor for sporadic Alzheimer’s disease.  Arterioscler Thromb Vasc Biol. 2003;  23 2055-2062
    Google Scholar
  • 49 Kivipelto M, Helkala E L, Hanninen T. et al . Midlife vascular risk factors and late-life mild cognitive impairment: A population-based study.  Neurology. 2001;  56 1683-1689
    Google Scholar
  • 50 Mielke M M, Zandi P P, Sjogren M. et al . High total cholesterol levels in late life associated with a reduced risk of dementia.  Neurology. 2005;  64 1689-1695
    Google Scholar
  • 51 Solfrizzi V, Panza F, Colacicco A M. et al . Vascular risk factors, incidence of MCI, and rates of progression to dementia.  Neurology. 2004;  63 1882-1891
    Google Scholar
  • 52 Panza F, Capurso C, D’Introno A. et al . Total cholesterol levels and the risk of mild cognitive impairment and Alzheimer’s disease.  J Am Geriatr Soc. 2007;  55 133-135
    Google Scholar
  • 53 Solomon A, Kareholt I, Ngandu T. et al . Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study.  Neurology. 2007;  68 751-756
    Google Scholar
  • 54 Wirths O, Thelen K, Breyhan H. et al . Decreased plasma cholesterol levels during aging in transgenic mouse models of Alzheimer’s disease.  Exp Gerontol. 2006;  41 220-224
    Google Scholar
  • 55 Solomon A, Kareholt I, Ngandu T. et al . Serum total cholesterol, statins and cognition in non-demented elderly.  Neurobiol Aging. 2007 Nov 15;  Epub ahead of print
    Google Scholar
  • 56 Heart Protection Study Collaborative Study Group . MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.  Lancet. 2002;  360 7-22
    Google Scholar
  • 57 Madero M, Gul A, Sarnak M J. Cognitive function in chronic kidney disease.  Semin Dial. 2008;  21 29-37
    Google Scholar
  • 58 Kurella M, Yaffe K, Shlipak M G. et al . Chronic kidney disease and cognitive impairment in menopausal women.  Am J Kidney Dis. 2005;  45 66-76
    Google Scholar
  • 59 Seliger S L, Siscovick D S, Stehman-Breen C O. et al . Moderate renal impairment and risk of dementia among older adults: the Cardiovascular Health Cognition Study.  J Am Soc Nephrol. 2004;  15 1904-1911
    Google Scholar
  • 60 Teng E L, Chui H C. The Modified Mini-Mental State (3 MS) examination.  J Clin Psychiatry. 1987;  48 314-318
    Google Scholar
  • 61 Kurella M, Chertow G M, Fried L F. et al . Chronic kidney disease and cognitive impairment in the elderly: the health, aging, and body composition study.  J Am Soc Nephrol. 2005;  16 2127-2133
    Google Scholar
  • 62 Olichney J M, Taylor J R, Gatherwright J. et al . Patients with MCI and N 400 or P 600 abnormalities are at very high risk for conversion to dementia.  Neurology. 2008;  70 1763-1770
    Google Scholar
  • 63 Madan P, Kalra O P, Agarwal S. et al . Cognitive impairment in chronic kidney disease.  Nephrol Dial Transplant. 2007;  22 440-444
    Google Scholar
  • 64 Kurella M, Chertow G M, Luan J. et al . Cognitive impairment in chronic kidney disease.  J Am Geriatr Soc. 2004;  52 1863-1869
    Google Scholar
  • 65 Stewart C A, Smith G E. Minimal hepatic encephalopathy.  Nat Clin Pract Gastroenterol Hepatol. 2007;  4 677-685
    Google Scholar
  • 66 Weissenborn K, Ennen J C, Schomerus H. et al . Neuropsychological characterization of hepatic encephalopathy.  J Hepatol. 2001;  34 768-773
    Google Scholar
  • 67 McCrea M, Cordoba J, Vessey G. et al . Neuropsychological characterization and detection of subclinical hepatic encephalopathy.  Arch Neurol. 1996;  53 758-763
    Google Scholar
  • 68 Ferenci P, Lockwood A, Mullen K. et al . Hepatic encephalopathy – definition, nomenclature, diagnosis, and quantification: final report of the working party at the 11th World Congresses of Gastroenterology, Vienna, 1998.  Hepatology. 2002;  35 716-721
    Google Scholar
  • 69 Groeneweg M, Quero J C, De Bruijn I. et al . Subclinical hepatic encephalopathy impairs daily functioning.  Hepatology. 1998;  28 45-49
    Google Scholar
  • 70 Lockwood A H. “What’s in a name?” Improving the care of cirrhotics.  J Hepatol. 2000;  32 859-861
    Google Scholar
  • 71 Clarke R, Refsum H, Birks J. et al . Screening for vitamin B-12 and folate deficiency in older persons.  Am J Clin Nutr. 2003;  77 1241-1247
    Google Scholar
  • 72 Lindenbaum J, Healton E B, Savage D G. et al . Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytosis.  N Engl J Med. 1988;  318 1720-1728
    Google Scholar
  • 73 Hin H, Clarke R, Sherliker P. et al . Clinical relevance of low serum vitamin B 12 concentrations in older people: the Banbury B 12 study.  Age Ageing. 2006;  35 416-422
    Google Scholar
  • 74 Malouf R, Areosa S astre A. Vitamin B 12 for cognition.  Cochrane Database Syst Rev. 2003;  (3) CD004326
    Google Scholar
  • 75 Kessler H, Bleich S, Falkai P. et al . Homozystein und Demenzerkrankungen.  Fortschr Neurol Psychiatr. 2003;  71 150-156
    Google Scholar
  • 76 Riggs K M, Spiro 3 rd A, Tucker K. et al . Relations of vitamin B-12, vitamin B-6, folate, and homocysteine to cognitive performance in the Normative Aging Study.  Am J Clin Nutr. 1996;  63 306-314
    Google Scholar
  • 77 Quadri P, Fragiacomo C, Pezzati R. et al . Homocysteine and B vitamins in mild cognitive impairment and dementia.  Clin Chem Lab Med. 2005;  43 1096-1100
    Google Scholar
  • 78 Tucker K L, Qiao N, Scott T. et al . High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study.  Am J Clin Nutr. 2005;  82 627-635
    Google Scholar
  • 79 Mooijaart S P, Gussekloo J, Frolich M. et al . Homocysteine, vitamin B-12, and folic acid and the risk of cognitive decline in old age: the Leiden 85-Plus study.  Am J Clin Nutr. 2005;  82 866-871
    Google Scholar
  • 80 Malouf M, Grimley E J, Areosa S A. Folic acid with or without vitamin B 12 for cognition and dementia.  Cochrane Database Syst Rev. 2003;  (4) CD004514
    Google Scholar
  • 81 Janowsky J S. Thinking with your gonads: testosterone and cognition.  Trends Cogn Sci. 2006;  10 77-82
    Google Scholar
  • 82 Tirassa P, Thiblin I, Agren G. et al . High-dose anabolic androgenic steroids modulate concentrations of nerve growth factor and expression of its low affinity receptor (p75-NGFr) in male rat brain.  J Neurosci Res. 1997;  47 198-207
    Google Scholar
  • 83 Zitzmann M, Weckesser M, Schober O. et al . Changes in cerebral glucose metabolism and visuospatial capability in hypogonadal males under testosterone substitution therapy.  Exp Clin Endocrinol Diabetes. 2001;  109 302-304
    Google Scholar
  • 84 Azad N, Pitale S, Barnes W E. et al . Testosterone treatment enhances regional brain perfusion in hypogonadal men.  J Clin Endocrinol Metab. 2003;  88 3064-3068
    Google Scholar
  • 85 Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship.  Eur J Endocrinol. 2006;  155 773-781
    Google Scholar
  • 86 Nieschlag E, Swerdloff R, Behre H M. et al . Investigation, treatment and monitoring of late-onset hypogonadism in males. ISA, ISSAM, and EAU recommendations.  Eur Urol. 2005;  48 1-4
    Google Scholar
  • 87 Cooper D S. Clinical practice. Subclinical hypothyroidism.  N Engl J Med. 2001;  345 260-265
    Google Scholar
  • 88 Canaris G J, Manowitz N R, Mayor G. et al . The Colorado thyroid disease prevalence study.  Arch Intern Med. 2000;  160 526-534
    Google Scholar
  • 89 Osterweil D, Syndulko K, Cohen S N. et al . Cognitive function in non-demented older adults with hypothyroidism.  J Am Geriatr Soc. 1992;  40 325-335
    Google Scholar
  • 90 Volpato S, Guralnik J M, Fried L P. et al . Serum thyroxine level and cognitive decline in euthyroid older women.  Neurology. 2002;  58 1055-1061
    Google Scholar
  • 91 Badgio P C, Worden B L. Cognitive functioning and aging in women.  J Women Aging. 2007;  19 13-30
    Google Scholar
  • 92 Burmeister L A, Ganguli M, Dodge H H. et al . Hypothyroidism and cognition: preliminary evidence for a specific defect in memory.  Thyroid. 2001;  11 1177-1185
    Google Scholar
  • 93 Davis J D, Stern R A, Flashman L A. Cognitive and neuropsychiatric aspects of subclinical hypothyroidism: significance in the elderly.  Curr Psychiatry Rep. 2003;  5 384-390
    Google Scholar
  • 94 Vardy J, Rourke S, Tannock I F. Evaluation of cognitive function associated with chemotherapy: a review of published studies and recommendations for future research.  J Clin Oncol. 2007;  25 2455-2463
    Google Scholar
  • 95 Minisini A, Atalay G, Bottomley A. et al . What is the effect of systemic anticancer treatment on cognitive function?.  Lancet Oncol. 2004;  5 273-282
    Google Scholar
  • 96 Anderson-Hanley C, Sherman M L, Riggs R. et al . Neuropsychological effects of treatments for adults with cancer: a meta-analysis and review of the literature.  J Int Neuropsychol Soc. 2003;  9 967-982
    Google Scholar
  • 97 Jansen C E, Miaskowski C, Dodd M. et al . A metaanalysis of studies of the effects of cancer chemotherapy on various domains of cognitive function.  Cancer. 2005;  104 2222-2233
    Google Scholar
  • 98 Hopkins R O, Jackson J C. Long-term neurocognitive function after critical illness.  Chest. 2006;  130 869-878
    Google Scholar
  • 99 Jackson J C, Hart R P, Gordon S M. et al . Six-month neuropsychological outcome of medical intensive care unit patients.  Crit Care Med. 2003;  31 1226-1234
    Google Scholar
  • 100 Hopkins R O, Weaver L K, Pope D. et al . Neuropsychological sequelae and impaired health status in survivors of severe acute respiratory distress syndrome.  Am J Respir Crit Care Med. 1999;  160 50-56
    Google Scholar
  • 101 Rothenhausler H B, Ehrentraut S, Stoll C. et al . The relationship between cognitive performance and employment and health status in long-term survivors of the acute respiratory distress syndrome: results of an exploratory study.  Gen Hosp Psychiatry. 2001;  23 90-96
    Google Scholar
  • 102 Hopkins R O, Weaver L K, Collingridge D. et al . Two-year cognitive, emotional, and quality-of-life outcomes in acute respiratory distress syndrome.  Am J Respir Crit Care Med. 2005;  171 340-347
    Google Scholar
  • 103 Mullges W, Berg D, Schmidtke A. et al . Early natural course of transient encephalopathy after coronary artery bypass grafting.  Crit Care Med. 2000;  28 1808-1811
    Google Scholar
  • 104 Keith J R, Puente A E, Malcolmson K L. et al . Assessing postoperative cognitive change after cardiopulmonary bypass surgery.  Neuropsychology. 2002;  16 411-421
    Google Scholar
  • 105 Selnes O A, Grega M A, Borowicz L M. et al . Cognitive changes with coronary artery disease: a prospective study of coronary artery bypass graft patients and nonsurgical controls.  Ann Thorac Surg. 2003;  75 1377-1384; discussion 1384 – 1376
    Google Scholar
  • 106 Selnes O A, McKhann G M. Neurocognitive complications after coronary artery bypass surgery.  Ann Neurol. 2005;  57 615-621
    Google Scholar
  • 107 Newman M F, Kirchner J L, Phillips-Bute Jr B. et al . Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery.  N Engl J Med. 2001;  344 395-402
    Google Scholar
  • 108 Selnes O A, Royall R M, Grega M A. et al . Cognitive changes 5 years after coronary artery bypass grafting: is there evidence of late decline?.  Arch Neurol. 2001;  58 598-604
    Google Scholar
  • 109 Stygall J, Newman S P, Fitzgerald G. et al . Cognitive change 5 years after coronary artery bypass surgery.  Health Psychol. 2003;  22 579-586
    Google Scholar
  • 110 Mullges W, Babin-Ebell J, Reents W. et al . Cognitive performance after coronary artery bypass grafting: a follow-up study.  Neurology. 2002;  59 741-743
    Google Scholar
  • 111 Potter G G, Plassman B L, Helms M J. et al . Age effects of coronary artery bypass graft on cognitive status change among elderly male twins.  Neurology. 2004;  63 2245-2249
    Google Scholar
  • 112 Hlatky M A BC, Boothroyd D. et al . Cognitive function 5 years after randomization to coronary angioplasty or coronary artery bypass graft surgery.  Circulation. 1999;  96 11-15
    Google Scholar
  • 113 McKhann G M, Grega M A, Borowicz L M. et al . Is there cognitive decline 1 year after CABG? Comparison with surgical and nonsurgical controls.  Neurology. 2005;  65 991-999
    Google Scholar
  • 114 Selnes O A, Zeger S L. Coronary artery bypass grafting baseline cognitive assessment: essential not optional.  Ann Thorac Surg. 2007;  83 374-376
    Google Scholar
  • 115 Perry Jr W, Hilsabeck R C, Hassanein T I. Cognitive dysfunction in chronic hepatitis C: a review.  Dig Dis Sci. 2008;  53 307-321
    Google Scholar
  • 116 Forton D M, Taylor-Robinson S D, Thomas H C. Central nervous system changes in hepatitis C virus infection.  Eur J Gastroenterol Hepatol. 2006;  18 333-338
    Google Scholar
  • 117 Forton D M, Thomas H C, Murphy C A. et al . Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease.  Hepatology. 2002;  35 433-439
    Google Scholar
  • 118 Hilsabeck R C, Hassanein T I, Carlson M D. et al . Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C.  J Int Neuropsychol Soc. 2003;  9 847-854
    Google Scholar
  • 119 McAndrews M P, Farcnik K, Carlen P. et al . Prevalence and significance of neurocognitive dysfunction in hepatitis C in the absence of correlated risk factors.  Hepatology. 2005;  41 801-808
    Google Scholar
  • 120 Cordoba J, Flavia M, Jacas C. et al . Quality of life and cognitive function in hepatitis C at different stages of liver disease.  J Hepatol. 2003;  39 231-238
    Google Scholar
  • 121 Lawson L J, Perry V H, Gordon S. Turnover of resident microglia in the normal adult mouse brain.  Neuroscience. 1992;  48 405-415
    Google Scholar
  • 122 Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection. Report of a Working Group of the American Academy of Neurology AIDS Task Force.  Neurology. 1991;  41 778-785
    Google Scholar
  • 123 Heaton R K, Grant I, Butters N. et al . The HNRC 500 – neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center.  J Int Neuropsychol Soc. 1995;  1 231-251
    Google Scholar
  • 124 Goodkin K, Wilkie F L, Concha M. et al . Aging and neuro-AIDS conditions and the changing spectrum of HIV-1-associated morbidity and mortality.  J Clin Epidemiol. 2001;  54 (Suppl 1) S35-S43
    Google Scholar
  • 125 White D A, Heaton R K, Monsch A U. Neuropsychological studies of asymptomatic human immunodeficiency virus-type-1 infected individuals. The HNRC Group. HIV Neurobehavioral Research Center.  J Int Neuropsychol Soc. 1995;  1 304-315
    Google Scholar
  • 126 Ances B M, Ellis R J. Dementia and neurocognitive disorders due to HIV-1 infection.  Semin Neurol. 2007;  27 86-92
    Google Scholar
  • 127 Valcour V G, Shikuma C M, Watters M R. et al . Cognitive impairment in older HIV-1-seropositive individuals: prevalence and potential mechanisms.  Aids. 2004;  18 (Suppl 1) S79-S86
    Google Scholar
  • 128 Hult B, Chana G, Masliah E. et al . Neurobiology of HIV.  Int Rev Psychiatry. 2008;  20 3-13
    Google Scholar
  • 129 Strachan M W, Price J F, Frier B M. Diabetes, cognitive impairment, and dementia.  Brit Med J. 2008;  336 6
    Google Scholar

Dr. Thorleif Etgen

Neurologische Klinik, Klinikum Traunstein

Cuno-Niggl-Straße 3

83278 Traunstein

Email: thorleif.etgen@klinikum-traunstein.de

      >